We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat interventions due to restenosis in the first 6 months) in 847 patients (fluvastatin [n = 417] or placebo [n = 430]) with average cholesterol levels treated with stents in the Lescol Intervention Prevention Study (LIPS). During the 4-year follow-up period, fluvastatin significantly decreased total cholesterol and low-density lipoprotein cholesterol levels and decreased the risk of first adverse atherosclerotic cardiac events by 30% compared with placebo (95% confidence interval -49 to -3.4, p = 0.03).

dx.doi.org/10.1016/j.amjcard.2003.08.076, hdl.handle.net/1765/59961
The American Journal of Cardiology
Department of Cardiology

Saia, F, de Feyter, P.J, Serruys, P.W.J.C, Lemos Neto, P.A, Arampatzis, C.A, Hendrickx, G.R, … Branzi, A. (2004). Effect of fluvastatin on long-term outcome after coronary revascularization with stent implantation. The American Journal of Cardiology, 93(1), 92–95. doi:10.1016/j.amjcard.2003.08.076